Open AccessIncidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experience
Author(s) -
Reyhan Yıldız,
Yavuz Demirel,
Vesile Dilşad Mungan,
Ömür Aydın,
Betül Ayşe Sin,
Meltem Ağca,
Sevim Bavbek
Publication year - 2022
Publication title -
tuberkuloz ve toraks/tüberküloz ve toraks
Language(s) - English
Resource type - Journals
ISSN - 0494-1373
DOI - 10.5578/tt.20229702
Subject(s) - omalizumab , medicine , mepolizumab , asthma , incidence (geometry) , atopy , pediatrics , immunoglobulin e , immunology , antibody , eosinophil , physics , optics
To assess the incidence and course of COVID-19 in patients with severe asthma/chronic spontaneous urticaria using biological agents.